ITGR — Integer Holdings Corp
ESEN Master AI Institutional Analysis | As of 2026-07-31 07:24 UTC | Health Care Sector
| Metric | Grade | Score | Evidence & Context | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 74 | Strong earnings momentum (49.7% YoY EPS growth), attractive forward valuation (16.6x PE), and hyper-growth classification offset by elevated trailing PE (33.1x) and weak profitability flags. Low beta (0.63) provides defensive characteristics in volatile environments. | 6-12M |
| Growth Sustainability & Moat | B+ | 76 | EPS growth of 49.7% YoY signals robust earnings expansion. Health Care sector positioning with 5.8% revenue growth YoY reflects steady operational momentum. PEG ratio of 0.67 indicates growth is priced reasonably relative to expansion rate. Hyper-growth flag confirmed. | 3-6M |
| Valuation & Safety (Pre-Penalty) | B | 71 | Trailing P/E of 33.1x is elevated on historical basis; however, forward P/E of 16.6x projects significant earnings accretion and normalization. Low dividend yield (not disclosed) and no dividend per share creates reinvestment optionality. Enterprise value aligned with market cap ($3.4B) signals clean capital structure. | 6-12M |
| Volatility & Drawdown Risk | A- | 82 | Beta of 0.63 indicates 37% lower volatility than S&P 500. Stock has traded within $62–$112 over 52 weeks; current price ($100.86) sits near upper band, suggesting equilibrium pricing. Low average volume (0.40M shares) warrants awareness of microstructure risk on larger orders. | Ongoing |
| Crowding Risk Flag | C+ | 62 | Hyper-growth classification and strong EPS momentum likely attract institutional interest; low trading volume suggests moderate retail participation. Forward P/E discount to trailing invites positioning ahead of earnings inflections. Monitor institutional fund ownership and short interest trends. | 1-3M |
| Institutional & Smart Money Flow | B | 68 | No explicit target price or earnings date disclosed; limits real-time signal clarity. Health Care sector breadth and company scale ($3.4B cap) support institutional eligibility. Pending earnings visibility essential for near-term flow dynamics. | 1-3M |
| Confidence Score | B | 72 | Data coverage strong on valuation, growth, and volatility metrics. Earnings date and target price absent; this introduces modest uncertainty on consensus views. Revenue and profitability flags ("strong_profitability": false) warrant forward earnings scrutiny. Assessment based on disclosed fundamentals and derived metrics. | 6-12M |
| Penalty Overlay | -5 | -5 | Weak profitability flag and lack of earnings date impose modest caution. Trailing P/E compression required for multiple normalization. No material red flags (high valuation flag negative, weak balance flag negative); penalty light relative to growth upside. | 6-12M |
Integer Holdings Corp operates within the Health Care sector, competing alongside diversified medical device, diagnostic, and contract manufacturing peers. The forward P/E multiple of 16.6x positions ITGR below many high-growth health tech names (often 20–35x forward) and aligns with mature medical device incumbents (12–18x), signaling balanced investor perception. The 49.7% EPS growth rate is substantially above Health Care sector median (~8–12%), confirming differentiated earnings quality. Beta of 0.63 places the stock in the defensive quartile, typical of essential medical supply chains and recurring-revenue business models. YTD return of -7.26% slightly lags the Health Care sector, though the 52-week range ($62–$112) reflects normal cyclicality for mid-cap industrials with medical exposure.
1–3 Month Window (Near-Term Tactical)
Key Driver: Pending earnings report and Q3 guidance. Absence of disclosed earnings date creates near-term opacity; upon announcement, expect volatility compression or expansion tied to EPS beat/miss cadence. Crowding risk (C+ grade) suggests positioning ahead of earnings inflection—watch for institutional accumulation or distribution signals. Trading range likely $98–$103 absent catalyst. Volume constraints (0.40M avg) may amplify intraday moves on earnings surprise.
6–12 Month Window (Medium-Term Strategic)
Key Driver: EPS accretion and P/E multiple normalization. Forward P/E of 16.6x implies market expects 50%+ earnings growth to materialize; if delivered, trailing multiple compresses to ~22x (normalized health care) and stock fair value rises to $115–$125. Hyper-growth classification, combined with 5.8% revenue growth and strong EPS momentum, supports mid-double-digit total return potential. Low beta (0.63) provides upside participation with reduced drawdown risk, attractive in rotational markets. Monitor capital allocation (reinvestment vs. buyback/dividend) as company scales.
• Weak Profitability Flag: "strong_profitability" metric is False; monitor margin trends and working capital efficiency. Ensure earnings growth is not driven by accounting or one-time items.
• Earnings Date Unknown: Absence of disclosed earnings date limits forward guidance visibility. Once announced, expect volatility; price target and analyst consensus unavailable for reality check.
• Valuation Compression: Trailing P/E of 33.1x requires forward P/E accretion (16.6x) to materialize; miss risks multiple contraction and downside to $85–$92.
• Liquidity Constraint: Average volume of 0.40M shares/day is modest; large block trades may move price; institutional exit risk on negative catalyst.
ESEN Master AI Score: 74 / 100
Grade: B+ | Recommendation: Accumulate on Weakness | Horizon: 6–12 Months
ITGR Stock Analysis & Forecast
Is ITGR a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
ITGR Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, ITGR shows balanced risk-reward characteristics.
Should You Buy ITGR Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in ITGR.